BusinessSummit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual MeetingBy Nasdaq OMXApr 20, 2018, 11:00 AM UTC
BusinessSummit Completes Dosing of Ezutromid in PhaseOut DMD Clinical TrialBy Nasdaq OMXApr 19, 2018, 11:01 AM UTC
BusinessSummit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical ConferenceBy Nasdaq OMXMar 14, 2018, 11:00 AM UTC
BusinessSummit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS CongressBy Nasdaq OMXOct 4, 2017, 11:00 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressBy Nasdaq OMXJun 14, 2017, 11:00 AM UTC
BusinessSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDBy Nasdaq OMXMay 15, 2017, 11:01 AM UTC
BusinessSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDBy Nasdaq OMXMay 15, 2017, 11:01 AM UTC
